Skip to main content
SpringerLink
Log in

Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice?

A conceptual review

  • REVIEW
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

This conceptual review summarises the results of relevant studies on antidepressants, mood stabilisers such as lithium and anticonvulsants, and second generation antipsychotics in the indication of bipolar depression. Based on methodological and clinical considerations, the position of antidepressants and the possible alternatives in this indication are reviewed very carefully. In addition the regulatory requirements for licensing a drug for the indication 'short–term treatment of bipolar depression' are described.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adli M, Bschor T, Canata B, Dopfmer S, Bauer M (1998) Lithium in the treatment of acute depression. Fortschr Neurol Psychiatr 66:435–441

    CAS  PubMed  Google Scholar 

  2. Altshuler L, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M, Mintz J (2001) The impact of antidepressant discontinuation versus antidepressant continuation on 1–year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 62:612–616

    CAS  PubMed  Google Scholar 

  3. Altshuler L, Suppes T, Black D, Nolen WA, Keck P–EJ, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, et al. (2003) Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1–year follow–up. Am J Psychiatry 160:1252–1262

    Article  PubMed  Google Scholar 

  4. American Psychiatric Association (APA) (1994) Diagnostic and statistical manual of mental disorders. 4th ed. , DSM–IV. APA, Washington DC

  5. American Psychiatric Association (APA) (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1–50

    Google Scholar 

  6. Andersen UA, Andersen M, Rosholm JU, Gram LF (2001) Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand 104:458–465

    Article  CAS  PubMed  Google Scholar 

  7. Angst J, Angst F, Gerber–Werder R, Gamma A (2005) Suicide in 406 mood–disorder patients with and without long–term medication: a 40 to 44 years' follow–up. Arch Suicide Res (In Press)

  8. Ascher J, Barnett S, Batey S (2001) Safety and tolerability of lamotrigine in controlled mood disorder trials. Presentation at the Annual Meeting of the American Psychiatric Association, New Orleans, USA, 5–10 May 2001

  9. Ballenger JC, Post RM (1980) Carbamazepine in manic–depressive illness: a new treatment. Am J Psychiatry 137:782–790

    CAS  PubMed  Google Scholar 

  10. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1:Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5–43

    PubMed  Google Scholar 

  11. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ (1999) Clinical practice guidelines for bipolar disorder from the department of veterans affairs. J Clin Psychiatry 60:9–21

    CAS  PubMed  Google Scholar 

  12. Bauer MS, Mitchner L (2004) What is a “mood stabilizer”? An evidence– based response. Am J Psychiatry 161:3–18

    PubMed  Google Scholar 

  13. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M (1993) A double–blind study of L–sulpiride versus amitriptyline in lithium–maintained bipolar depressives. Acta Psychiatr Scand 88:434–439

    CAS  PubMed  Google Scholar 

  14. Bottlender R, Jager M, Strauss A, Möller H–J (2000) Suicidality in bipolar compared to unipolar depressed inpatients. Eur Arch Psychiatry Clin Neurosci 250:257–261

    Article  CAS  PubMed  Google Scholar 

  15. Bottlender R, Rudolf D, Strauß A, Möller HJ (2001) Mood–stabilisers reduce the risk of developing antidepressant–induced maniform states in acute treatment of bipolar I depressed patients. J Aff Disord 63:79–83

    CAS  Google Scholar 

  16. Bottlender R, Rudolf D, Jäger M, Strauss A, Möller HJ (2002) Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur Psychiatry 17:1–6

    Article  Google Scholar 

  17. Bowden CL (2002) Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 3:1513–1519

    Article  CAS  PubMed  Google Scholar 

  18. Broich K (2003) Is bipolar depression a different indication? A European regulatory point of view. Presentation at the 16th ECNP, Prague, 20–24 September 2003

  19. Calabrese JR, Delucchi GA (1990) Spectrum of efficacy of valproate in 55 patients with rapid–cycling bipolar disorder. Am J Psychiatry 147:431–434

    CAS  PubMed  Google Scholar 

  20. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double–blind placebo–controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88

    CAS  PubMed  Google Scholar 

  21. Calabrese J, MacFadden W, McCoy R, Minkwitz M, Wilson E, Mullen J (2004a) Double–blind, placebo–controlled study of quetiapine in bipolar depression. Abstract presented at APA 2004, NYC, USA

  22. Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH (2004b) International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry 65:571–579

    Google Scholar 

  23. Cohn JB, Collins G, Ashbrook E, Wernicke JF (1989) A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 4:313–322

    CAS  PubMed  Google Scholar 

  24. CPMP (2001) CPMP/EWP/567/98. Note for guidance on clinical evaluation of medicinal products in the treatment and prevention of bipolar disorder. http://www. emea. eu. int/pdfs/human/ ewp/056798en

  25. CPMP (2002) CPMP/EWP/518/97, Rev. 1. Note for guidance on clinical evaluation of medicinal products in the treatment of depression. http://www. edea. eu. int/pdfs/human/ewp/051897en

  26. De Wilde JE, Doogan DP (1982) Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 4:249–259

    Article  CAS  PubMed  Google Scholar 

  27. Dilsaver SC, Swann SC, Chen YW, Shoaib A, Joe B, Krajewski KJ, Gruber N, Tsai Y (1996) Treatment of bipolar depression with carbamazepine: results of an open study. Biol Psychiatry 40:935–937

    Article  CAS  PubMed  Google Scholar 

  28. Fieve RR, Platman SR, Plutchik RR (1968) The use of lithium in affective disorders. I. Acute endogenous depression. Am J Psychiatry 125:487–491

    CAS  PubMed  Google Scholar 

  29. Frances AJ, Docherty JP, Kahn DA (1996) The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 57(Suppl 12A):3–88

    Google Scholar 

  30. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL (1998) The Expert Consensus Guidelines for treating depression in bipolar disorder. J Clin Psychiatry 59(Suppl 4):73–79

    PubMed  Google Scholar 

  31. Freyhan FA (1957) Psychomotility, extrapyramidal syndrome and mode of action of neuroleptic therapies, chlorpromazine, reserpine and prochlorperazine. Nervenarzt 28:504–509

    CAS  PubMed  Google Scholar 

  32. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora–Ocatelli G, Leverich GS, Post RM (2000) A placebo–controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607–614

    Article  CAS  PubMed  Google Scholar 

  33. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM (2004) Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161:1537–1547

    Article  PubMed  Google Scholar 

  34. Goodwin GM (2003) Evidence–based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17:149–173

    Article  CAS  PubMed  Google Scholar 

  35. Goodwin GM, Nolen WA (1997) Treatment of bipolar depressive mood disorders: algorithms for pharmacotherapy. Int J Psychiatry Clin Prac 1(Suppl 1):S9–S12

    Google Scholar 

  36. Grossman F, Potter WZ, Brown EA, Maislin G (1999) A doubleblind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord 56:237–243

    Article  CAS  PubMed  Google Scholar 

  37. Grunze H, Möller HJ (2003) The use of atypical antipsychotics in bipolar spectrum disorders. Indian J Psychiatry 45:10–15

    Google Scholar 

  38. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ (2002) World Federation of Societies of Biological Psychiary (WFSBP) guidelines for biological treatment of bipolar diorders, Part I: Treatment of bipolar depression. World J Biol Psychiatry 3:115–124

    PubMed  Google Scholar 

  39. Hahn CG, Gyulai L, Baldassano CF, Lenox RH (2004) The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 65:791–804

    CAS  PubMed  Google Scholar 

  40. Himmelhoch JM, Fuchs CZ, Symons BJ (1982) A double–blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 170:628–634

    CAS  PubMed  Google Scholar 

  41. Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910–916

    CAS  PubMed  Google Scholar 

  42. Hirschfeld RMA, Clayton PJ, Cohen I, Fawcett J, Keck P, McClellan J, McElroy S, Post R, SatloffA (1994) Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 151:1–36

    Google Scholar 

  43. Hirschfeld RMA, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, et al. (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826–837

    CAS  PubMed  Google Scholar 

  44. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) The long–term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:530–537

    PubMed  Google Scholar 

  45. Kasper S, Haushofer M, Zapotoczky HG, Aschauer H, Wolf R, Hinterhuber H, Bonelli M, Wuschitz A (1999) Konsensus–Statement: Diagnostik und Therapie der bipolaren Störung. Neuropsychiatrie 13:100–108

    Google Scholar 

  46. Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152–3160

    Article  PubMed  Google Scholar 

  47. Khan A, Brown WA (2001) The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol 21:123–125

    Article  CAS  PubMed  Google Scholar 

  48. Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311–317

    CAS  PubMed  Google Scholar 

  49. Khan A, Khan SR, Leventhal RM, Brown WA (2001) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 4:113–118

    Article  CAS  PubMed  Google Scholar 

  50. Khan A, Khan S, Brown WA (2002a) Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 5:193–197

    Article  CAS  Google Scholar 

  51. Khan A, Leventhal RM, Khan SR, Brown WA (2002b) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40–45

    Article  Google Scholar 

  52. Khan A, Khan SR, Walens G, Kolts R, Giller EL (2003) Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 28:552–557

    Article  CAS  PubMed  Google Scholar 

  53. Khan MC, Wickham EA, Reed JV (1987) Lithium versus placebo in acute depression: a clinical trial. Int Clin Psychopharmacol 2:47–54

    CAS  PubMed  Google Scholar 

  54. Kusumakar V, Yatham LN, Haslam DR, Parikh SV, Matte R, Silverstone PH, Sharma V (1997) Treatment of mania, mixed state, and rapid cycling. Can J Psychiatry 42(Suppl 2):79S–86S

    PubMed  Google Scholar 

  55. Laakman G, Blaschke D, Hippius H, Messerer D (1986) Alprazolam versus amitriptyline in the treatment of depressed out–patients: a randomized double–blind trial. In: Lader HL, Davies HC (eds) Drug treatment of neurotic disorders. Edinburgh London Melbourne New York, Churchill Livingstone, pp 129–136

  56. Lambert PA (1984) Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HE, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam, Elsevier Science Publishers, pp 33–44

  57. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J (2004) A 52–week, open–label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 65:204–210

    CAS  PubMed  Google Scholar 

  58. Mendels J (1976) Lithium in the treatment of depression. Am J Psychiatry 133:373–378

    CAS  PubMed  Google Scholar 

  59. Mendlewicz J, Youdim MB (1980) Antidepressant potentiation of 5–hydroxytryptophan by L–deprenil in affective illness. J Affect Disord 2:137–146

    CAS  PubMed  Google Scholar 

  60. Möller HJ (1992) Klinische Prüfstudien. Allgemeine Grundlagen der Pharmakopsychiatrie. Riederer P, Laux G, and Pöldinger W Neuro–Psychopharmaka. 1. Wien New York, Springer, pp 177–199

  61. Möller HJ (2005a) Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 255:83–93

    Google Scholar 

  62. Möller HJ (2005b) Antipsychotic and antidepressive effects of second generation antipsychotics – two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci (In Press)

  63. Möller H–J, Grunze H (2000) Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 250:57–68

    PubMed  Google Scholar 

  64. Möller HJ, Bottlender R, Grunze H, Strauss A, Wittmann J (2001) Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Aff Disord 67:141–146

    Google Scholar 

  65. Montgomery DB (2001) ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 11:79–88

    Article  CAS  PubMed  Google Scholar 

  66. Montgomery SA, Lecrubier Y (1999) Is severe depression a separate indication? ECNP Consensus Meeting September 20:1996, Amsterdam. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 9:259–264

    CAS  PubMed  Google Scholar 

  67. Motohashi N (1999) Algorithms for the pharmacotherapy of bipolar disorder. Psychiatry and Clinical Neurosciences 53:S41–S44

    PubMed  Google Scholar 

  68. Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, Oakes R, Pitts CD (2001) Double–blind, placebo–controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158:906–912

    CAS  PubMed  Google Scholar 

  69. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J (2002) Lamotrigine as adjunct to paroxetine in acute depression: a placebo–controlled, double–blind study. J Clin Psychiatry 63:337–344

    CAS  PubMed  Google Scholar 

  70. Post RM, Uhde TW, Roy BP, Joffe RT (1986) Antidepressant effects of carbamazepine. Am J Psychiatry 143:29–34

    CAS  PubMed  Google Scholar 

  71. Post RM, Leverich GS, Denicoff KD, Frye MA, Kimbrell TA, Dunn R (1997) Alternative approaches to refractory depression in bipolar illness. Depress Anxiety 5:175–189

    Article  CAS  PubMed  Google Scholar 

  72. Roth BL, Sheffler D, Potkin SG (2003) Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res 3:108–117

    CAS  Google Scholar 

  73. Sachs GS (1996) Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 16:32S–47S

    CAS  PubMed  Google Scholar 

  74. Sachs GS (2005) What is a mood stabilizer? Clin Appro in Bipolar Disorders 4:3

    Google Scholar 

  75. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF (1994) A double–blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55:391–393

    CAS  PubMed  Google Scholar 

  76. Sachs GS, Koslow CL, Ghaemi SN (2000a) The treatment of bipolar depression. Bipolar Disord 2:256–260

    Article  CAS  Google Scholar 

  77. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP (2000b) The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med Spec 1–104

  78. Sachs G, Collins MA, Altshuler L, Ketter T, Suppes T, Rasgon N, Frye M, Wozniak P, Tracy K, Sommerville KW (2002) Divalproex sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus and Proceedings Summary

  79. Severus WE, Grunze H, Kleindienst N, Möller HJ (2005) The efficacy of lithium as maintenance treatment in bipolar disorder in the light of new approval studies. Clin Psychopharm (Submitted)

  80. Silverstone T (2001) Moclobemide vs. imipramine in bipolar depression: a multicentre double–blind clinical trial. Acta Psychiatr Scand 104:104–109

    Article  CAS  PubMed  Google Scholar 

  81. Souza FG, Goodwin GM (1991) Lithium treatment and prophylaxis in unipolar depression: a meta–analysis. Br J Psychiatry 158:666–675

    CAS  PubMed  Google Scholar 

  82. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW (2001) Short–term efficacy of tricyclic antidepressants revisited: a meta–analytic study. Eur Neuropsychopharmacol 11:173–180

    CAS  PubMed  Google Scholar 

  83. Svestka J, Deskova E, Rysanek R, Nahunek K (1991) Antiepileptics in the treatment of endogenous depression. Proceedings IVth World Congress of Biological Psychiatry

  84. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al. (2003) Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088

    CAS  PubMed  Google Scholar 

  85. Walden J, Grunze H, Schlösser S, Berger M, Bergmann A, Bräunig P, Dose M, Emrich HE, Gastpar M, Greil W, et al. (1999) Empfehlungen für die Behandlung bipolarer affektiver Störungen (Recommendations for the treatment of bipolar affective disorder). Psychopharmakotherapie 6:115–123

    Google Scholar 

  86. Winsberg ME, DeGolia SG, Strong CM, Ketter TA (2001) Divalproex therapy in medication–naive and mood–stabilizer–naive bipolar II depression. J Affect Disord 67:207–212

    Article  CAS  PubMed  Google Scholar 

  87. Yatham LN, Kusumakar V, Parikh SV, Haslam DR, Matte R, Sharma V, Kennedy S (1997) Bipolar depression: treatment options. Can J Psychiatry 42(Suppl 2):87S–91S

    PubMed  Google Scholar 

  88. Young LT (2004) What exactly is a mood stabilizer? J Psychiatry Neurosci 29:87–88

    PubMed  Google Scholar 

  89. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis– Siotis I (2000) Double–blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 157:124–126

    Article  CAS  PubMed  Google Scholar 

  90. Zornberg GL, Pope Jr HG (1993) Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 13:397–408

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstrasse 7, 80336, Munich, Germany

    H.-J. Möller & H. Grunze

  2. Bundesinstitut für Arzneimittel (BfArM), Bonn, Germany

    K. Broich

Authors
  1. H.-J. Möller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Grunze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Broich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.-J. Möller.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möller, HJ., Grunze, H. & Broich, K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice?. Eur Arch Psychiatry Clin Neurosci 256, 1–16 (2006). https://doi.org/10.1007/s00406-005-0591-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-005-0591-9

Key words

Search

Navigation